In this study, we examine the therapeutic potential of the NIS-expressing Vaccinia virus (VV-NIS), GLV-1h153 (VV-NIS), as an oncolytic agent and as a vector for targeting NIS gene therapy to prostate cancer cells in vitro and in vivo. This evidence concerns the gene SLC5A5 and prostate carcinoma.